RT Journal Article
SR Electronic
T1 High prevalence of long-term psychophysical olfactory dysfunction in patients with COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.07.21249406
DO 10.1101/2021.01.07.21249406
A1 Boscolo-Rizzo, Paolo
A1 Menegaldo, Anna
A1 Fabbris, Cristoforo
A1 Spinato, Giacomo
A1 Borsetto, Daniele
A1 Vaira, Luigi Angelo
A1 Calvanese, Leonardo
A1 Pettorelli, Andrea
A1 Sonego, Massimo
A1 Frezza, Daniele
A1 Bertolin, Andy
A1 Cestaro, Walter
A1 Rigoli, Roberto
A1 Tirelli, Giancarlo
A1 Mosto, Maria Cristina Da
A1 Menini, Anna
A1 Polesel, Jerry
A1 Hopkins, Claire
YR 2021
UL http://medrxiv.org/content/early/2021/01/08/2021.01.07.21249406.abstract
AB This study prospectively assessed the long-term prevalence of self-reported and psychophysically measured olfactory dysfunction in subjects with mild-to-moderate COVID-19. Self-reported smell or taste impairment was prospectively evaluated by SNOT-22 at diagnosis, 4-week, 8-week, and 6-month. At 6 months from the diagnosis, psychophysical evaluation of olfactory function was also performed using the 34-item culturally adapted University of Pennsylvania Smell Identification Test (CA-UPSIT). 145 completed both the 6-month subjective and psychophysical olfactory evaluation. According to CA-UPSIT, 87 subjects (60.0%) exhibited some smell dysfunction, with 54 (37.2) being mildly microsmic, 16 (11.0%) moderately microsmic, 7 (4.8%) severely microsmic, and 10 patients (6.9%) being anosmic. At the time CA-UPSIT was administered, a weak correlation was observed between the self-reported alteration of sense of smell or taste and olfactory test scores (Spearman’s r=-0.26). Among 112 patients who self-reported normal sense of smell at last follow-up, CA-UPSIT revealed normal smell in 46 (41.1%), mild microsmia in 46 (41.1%), moderate microsmia in 11 (9.8%), severe microsmia in 3 (2.3%), and anosmia in 6 (5.4%) patients; however, of those patients self-reporting normal smell but who were found to have hypofunction on testing, 62 out of 66 had self-reported reduction in sense of smell or taste at an earlier time point. Despite most patients report a subjectively normal sense of smell, we observed a high percentage of persistent smell dysfunction at 6 months from the diagnosis of SARS-CoV-2 infection, with 11.7% of patients being anosmic or severely microsmic. These data highlight a significant long-term rate of smell alteration in patients with previous SARS-CoV-2 infection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was conducted with the approval of the ethic committee for clinical experimentation of Treviso and Belluno provinces (ethic vote: 780/CE).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll relevant data are within the paper and its Supporting Information files.